An interventional study of Cleanser, Moisturizer, and Sunscreen in Post - Inflammatory Hyperpigmentation and Pigmentation, sponsored by Revision Skincare. Completed at 1 site in United States. Open to female participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Revision Skincare · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hyperpigmentation with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Hyperpigmentation · United States.
Among the 35 studies in Hyperpigmentation with a site in United States, this one is the 29th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2026, is one of 20 with no phase, and was the 35th registered.
128 studies on the registry are indexed under Hyperpigmentation; 28 are open to participants now.
Browse Hyperpigmentation studies →2 of the 35 studies in Hyperpigmentation with a site in United States are open now. Recruiting first, the newest first:
Montefiore Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Hyperpigmentation studies recruiting now, 8 (50%) set no upper age limit and 8 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 25 Years to 55 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 2 · Phase 4 7
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 32 across 114 interventional studies indexed under Hyperpigmentation.
Median enrollment 21 across the 32 interventional studies, 44 across the 3 observational. Of the 29 that completed or were terminated, 8 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 35 have an industry lead sponsor. The 10 most frequent:
Revision Skincare is the lead sponsor of 20 studies on the registry; 1 is open to participants now.
Revision Skincare has 5 studies filed under Hyperpigmentation — fewer than ten, so there is no comparison to draw.
1 of the studies in Hyperpigmentation with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07896486Weill Medical College of Cornell UniversityEvaluating a Brightening Serum for Post-Inflammatory Hyperpigmentation | 2027-01-15 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Hyperpigmentation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This 12- week, single-center, open-label case study is being conducted to assess the efficacy and tolerance of a brightening skincare regimen comprised of a facial wash, brightening serum, brightening exfoliating pads, face cream and sunscreen by healthy females with clinically determined mild to moderate Post-inflammatory hyperpigmentation (PIH).
At Visit 1, prior to the start of the study, prospective subjects will be screened for eligibility requirements based on inclusion and exclusion criteria and will be enrolled into the study. Prospective subjects will be given an Institutional Review Board (IRB)-approved Informed Consent Form (ICF) and photography release form (PRF) to read and sign. Subjects will be provided the pre-washout skincare products, written usage instructions, and a daily diary.
At Baseline (Visit 2), subjects will have their face evaluated by a board-certified dermatology for clinical efficacy parameters (skin tone evenness, overall appearance, and PIH) and evaluate tolerability (Erythema, edema, and dryness) parameters. Subjects will then rate the Itching, Burning, and Stinging and complete a self-assessment questionnaire (SAQ). A clinical staff will take standardized clinical photographs using VISIA® Imaging.
At Visit 3, 4, 5, and 6 dermatologist clinical efficacy and tolerability, as well as subject tolerability assessments will be performed, followed by clinical photography. Subjects will complete an SAQ before the visit ends.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
From baseline to week 12, subjects will apply a Brightening Serum (2x daily), and brightening pads 3 times per week in the evening only (Monday, Wednesday, Friday) or (Tuesday, Thursday, Saturday).
Other: Cleanser, Moisturizer, and Sunscreen
From baseline to week 12, subjects will use a Brightening Facial Wash (2x daily), Facial Moisturizer (2x daily), and broad-spectrum sunscreen moisturizer SPF 50 (morning only). Participants were asked to apply the sunscreen if sun exposure was more than 30 minutes per day.
Improvement of Clinical Efficacy Parameters at 2, 4, 8, and 12 weeks versus Baseline
A board-certified dermatologist will grade skin tone evenness, overall appearance, and PIH at baseline and at weeks 2, 4, 8, and 12. Skin tone evenness and overall appearance will be graded using the modified Griffiths 10-point scale (0 = Even healthy skin color; 9 = Uneven, discolored appearance), while PIH will be measured using a 4-point investigator global assessment scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). Higher scores indicate greater severity of the respective skin condition, where a decrease in score indicates an improvement.
Time frame: Weeks 2, 4, 8, and 12 compared to baseline
Measurement of subject self assessment questionnaire
Subjects will complete a self-assessment questionnaire which will consist of a series of questions related to subjects' evaluation of product efficacy and attributes. Subjects are asked to rate based on a scoring system of the following: from 5 (completely agree) to 1 (completely disagree). The best outcome is to Completely Agree with the statement / question being asked.
Time frame: Baseline, weeks 2, 4, 8, and 12
Lack of Significant Increase in Objective Tolerability Parameters at weeks, 2, 4, 8, 12 compared to Baseline
Clinical grading of Objective Irritation Parameters (Erythema, Edema, and Dryness) evaluated by investigator and subject reporting of Subjective Irritation Parameters (Burning, Stinging, Itching) using a 4 point scale: 0 = None to 3 = Severe. A change in scores or lack of significant change at week 2, 4, 8 and 12 compared to Baseline indicates tolerability/safety of the test material. A lower score indicating a better outcome.
Time frame: Baseline, weeks 2, 4, 8, and 12
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Jul 2026, 4 months.
Of 28 industry-sponsored interventional studies with no phase under Hyperpigmentation, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 7. This study's 4 months is above that.
Counting every sponsor, half of 65 studies reached it within 7 months; a quarter within 3 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Revision Skincare